source
- Lilly shares slide as Foundayo prescriptions lag expectations, while Novo's Wegovy gains momentumEli Lilly's stock fell nearly 5% after the latest weekly prescription count for its obesity drug Foundayo missed analysts' expectations. IQVIA data showed U.S. prescriptions for Foundayo reached 3…
- Trump announces drug pricing deal with Regeneron, completing White House's 17-deal targetPresident Trump announced a drug‑pricing agreement with Regeneron Pharmaceuticals, marking the final deal in the administration's goal of securing 17 pricing arrangements. The agreement is intende…